SurModics to Present at the ThinkEquity Partners Growth Conference and the CL King Best Ideas Conference
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 11, 2007--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Bruce Barclay, President & CEO, will make a presentation to the investment community at the 5th Annual ThinkEquity Partners Growth Conference on Tuesday, September 18, 2007 at 6:30 p.m. (ET) at the St. Regis Hotel in San Francisco, California.
In addition, Phil Ankeny, Senior Vice President and Chief Financial Officer, is scheduled to make a presentation at the 5th Annual CL King Best Ideas Conference on Wednesday, September 19, 2007 at 9:00 a.m. (ET) at the Omni Berkshire Place Hotel in New York City.
Interested parties may access a live webcast of the presentations by logging on to the Investors section of the SurModics website at www.surmodics.com. Investors are advised to visit the site at least 10 minutes before the scheduled presentation to register, download and install any necessary multimedia streaming software. The software plug-ins required for the live event are either RealPlayer or Windows Media Player. The audio file of this webcast will be archived and available on the company's web site for 30 days.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in better patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
CONTACT: SurModics, Inc.
Senior Vice President and Chief Financial Officer
SOURCE: SurModics, Inc.